IL22 and myeloid sarcoma: In conclusion, we have shown (i) that MS patients in relapse harbor significantly higher serum levels of IL-22, (ii) that astrocytes express the IL-22 receptor, (iii) that there is a colocalization of IL-22 with astrocytes, and (iv) that IL-22 has pro-survival properties on primary human astrocytes.